Cargando…

Aripiprazole for late-life schizophrenia

Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating...

Descripción completa

Detalles Bibliográficos
Autores principales: Rado, Jeffrey, Janicak, Philip G
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938032/
https://www.ncbi.nlm.nih.gov/pubmed/20852672
_version_ 1782186564791566336
author Rado, Jeffrey
Janicak, Philip G
author_facet Rado, Jeffrey
Janicak, Philip G
author_sort Rado, Jeffrey
collection PubMed
description Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high co-morbidity rates (both psychiatric and medical) in the elderly; age-related changes in pharmacokinetics leading to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole.
format Text
id pubmed-2938032
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29380322010-09-17 Aripiprazole for late-life schizophrenia Rado, Jeffrey Janicak, Philip G Clin Interv Aging Review Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high co-morbidity rates (both psychiatric and medical) in the elderly; age-related changes in pharmacokinetics leading to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole. Dove Medical Press 2010 2010-09-07 /pmc/articles/PMC2938032/ /pubmed/20852672 Text en © 2010 Rado and Janicak, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Rado, Jeffrey
Janicak, Philip G
Aripiprazole for late-life schizophrenia
title Aripiprazole for late-life schizophrenia
title_full Aripiprazole for late-life schizophrenia
title_fullStr Aripiprazole for late-life schizophrenia
title_full_unstemmed Aripiprazole for late-life schizophrenia
title_short Aripiprazole for late-life schizophrenia
title_sort aripiprazole for late-life schizophrenia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938032/
https://www.ncbi.nlm.nih.gov/pubmed/20852672
work_keys_str_mv AT radojeffrey aripiprazoleforlatelifeschizophrenia
AT janicakphilipg aripiprazoleforlatelifeschizophrenia